FreedomIntelligence

Armored CAR-T Design Agent

489
57
# Install this skill:
npx skills add FreedomIntelligence/OpenClaw-Medical-Skills --skill "Armored CAR-T Design Agent"

Install specific skill from multi-skill repository

# Description

'AI-powered design of armored CAR-T cells with cytokine/chemokine expression for enhanced solid tumor efficacy, including IL-12, IL-15, IL-18, and IL-7 armoring strategies.'

# SKILL.md


name: 'armored-cart-design-agent'
description: 'AI-powered design of armored CAR-T cells with cytokine/chemokine expression for enhanced solid tumor efficacy, including IL-12, IL-15, IL-18, and IL-7 armoring strategies.'
measurable_outcome: Execute skill workflow successfully with valid output within 15 minutes.
allowed-tools:
- read_file
- run_shell_command


Armored CAR-T Design Agent

The Armored CAR-T Design Agent provides AI-assisted design of next-generation armored CAR-T cells engineered to express cytokines, chemokines, or other enhancing factors. These armored T cells overcome solid tumor challenges including immunosuppressive TME, poor trafficking, and T cell exhaustion, with recent clinical success in lymphoma (IL-18) and ongoing trials with IL-12, IL-15, and IL-7.

When to Use This Skill

  • When designing CAR-T cells for solid tumor applications.
  • For selecting optimal armoring payloads (cytokines, chemokines).
  • To optimize cytokine expression levels and regulation.
  • When engineering safety switches for armored constructs.
  • For predicting armored CAR-T efficacy and safety profiles.

Core Capabilities

  1. Armoring Payload Selection: Choose optimal cytokines for tumor type.

  2. Expression Level Optimization: Balance efficacy vs toxicity.

  3. Inducible System Design: Engineer regulated expression systems.

  4. Safety Switch Integration: Design kill switches and controls.

  5. Construct Optimization: Optimize transgene configuration.

  6. Efficacy Prediction: Predict enhanced tumor killing.

Armoring Strategies

Cytokine Mechanism Clinical Status Tumor Types
IL-12 Th1 polarization, IFN-gamma Phase I/II Solid tumors
IL-15 T/NK persistence Phase I/II Hematologic, solid
IL-18 Inflammasome, IFN-gamma Phase I (promising) Lymphoma
IL-7 T cell survival Phase I Multiple
IL-21 T cell proliferation Preclinical Multiple
CCL19/21 T cell trafficking Preclinical Solid tumors

Construct Architecture Options

Component Options Consideration
Promoter EF1a, PGK, CAG, NFAT-inducible Expression level/timing
Signal Peptide Native, IL-2ss, IgK Secretion efficiency
Cytokine Membrane-bound vs secreted Local vs systemic
Linker T2A, P2A, IRES Co-expression efficiency
Kill Switch iCasp9, HSV-TK, CD20 Safety control
Position Before/after CAR Expression balance

Workflow

  1. Input: Target tumor type, TME characteristics, CAR design.

  2. Payload Selection: Rank armoring strategies for tumor context.

  3. Expression Design: Optimize promoter, levels, regulation.

  4. Safety Engineering: Add appropriate control switches.

  5. Construct Assembly: Generate optimized DNA sequence.

  6. Efficacy Prediction: Model enhanced killing and persistence.

  7. Output: Optimized armored CAR construct with annotations.

Example Usage

User: "Design an armored CAR-T for pancreatic cancer targeting mesothelin with IL-12 armoring for TME remodeling."

Agent Action:

python3 Skills/Immunology_Vaccines/Armored_CART_Design_Agent/design_armored_cart.py \
    --car_target mesothelin \
    --tumor_type pancreatic \
    --armoring_payload IL-12 \
    --expression_system NFAT_inducible \
    --safety_switch iCasp9 \
    --backbone lentiviral \
    --optimize_codon human \
    --output armored_cart_design/

Output Components

Output Description Format
Construct Sequence Full transgene DNA .fasta, .gb
Construct Map Annotated visualization .png, .pdf
Expression Model Predicted levels .json
Safety Analysis Risk assessment .json
Manufacturing Guide Production recommendations .md
Predicted Efficacy Tumor killing model .json

IL-12 Armoring Details

Aspect Design Choice Rationale
Configuration Tethered IL-12 (p70) Localized, reduced toxicity
Expression NFAT-inducible Activation-dependent
Dose Low-level expression Safety optimization
Combination With PD-1 knockout Enhanced activity

IL-18 Armoring Details

Aspect Design Choice Rationale
Configuration Secreted mature IL-18 Enhanced IFN-gamma
Expression Constitutive or inducible Context-dependent
Clinical Results Lymphoma responses Validated approach
Combination With IL-21 Synergistic

IL-15 Armoring Details

Aspect Design Choice Rationale
Configuration Membrane-tethered IL-15/IL-15Ra Cis-presentation
Expression Constitutive moderate Persistence without toxicity
Benefit Reduced IL-2 dependence Manufacturing advantage
Safety Lower CRS risk Clinical benefit

AI/ML Components

Payload Selection:
- TME profiling to match cytokine needs
- Multi-objective optimization
- Clinical outcome modeling

Expression Optimization:
- Promoter strength prediction
- Codon optimization
- mRNA stability modeling

Safety Prediction:
- CRS/ICANS risk modeling
- Off-tumor activity prediction
- Systemic cytokine levels

Safety Considerations

Risk Mitigation Implementation
Cytokine storm Inducible expression NFAT promoter
Systemic toxicity Membrane tethering Localized effect
Uncontrolled proliferation Kill switch iCasp9
On-target off-tumor Regulatable CAR Logic gates

Clinical Trials (2025-2026)

Trial Armoring Target Cancer Status
NCT03721068 IL-18 CD19 Lymphoma Phase I (positive)
NCT04119024 IL-12 GD2 Neuroblastoma Phase I
NCT03932565 IL-15/21 CD19 B-ALL Phase I
Multiple IL-7/CCL19 Various Solid Preclinical

Prerequisites

  • Python 3.10+
  • Biopython for sequence handling
  • CAR design databases
  • Codon optimization tools
  • Structure prediction (optional)
  • CART_Design_Optimizer_Agent - Base CAR optimization
  • NK_Cell_Therapy_Agent - NK cell engineering
  • Cytokine_Storm_Analysis_Agent - Safety analysis
  • TCell_Exhaustion_Analysis_Agent - Exhaustion prevention

Manufacturing Considerations

Aspect Armored CAR Challenge Solution
Vector Size Larger transgene Optimize construct
Transduction Lower efficiency Increase MOI
Expansion Cytokine effects Tune expression
Characterization Complex phenotype Enhanced QC

Special Considerations

  1. Tumor Type Matching: Different tumors need different armoring
  2. Expression Timing: Constitutive vs inducible tradeoffs
  3. Dose Finding: Balance efficacy vs toxicity
  4. Combination: Consider with checkpoint knockout
  5. Manufacturing: Larger constructs affect production

Efficacy Enhancement Mechanisms

Mechanism Cytokine Effect
Persistence IL-15, IL-7 Longer survival
TME Remodeling IL-12 M2β†’M1, DC activation
Bystander Killing IL-18 Enhanced IFN-gamma
Trafficking CCL19/21 T cell recruitment
Anti-exhaustion IL-21 Stem-like maintenance

Author

AI Group - Biomedical AI Platform

# Supported AI Coding Agents

This skill is compatible with the SKILL.md standard and works with all major AI coding agents:

Learn more about the SKILL.md standard and how to use these skills with your preferred AI coding agent.